Table 1.

Potential therapeutic agents targeting the inflammasome pathway in myeloid malignancies.

Target biomolecule	Therapeutic agent	Feature	Disease targeted	Stage of development	Clinical trial identifier
CD33 receptor	BI 836858	Anti-CD33 monoclonal antibody	MDS AML	Phase 1/2 terminated Phase 1	NCT02240706 NCT03013998
	AMV564	CD33/CD3 BiTE	Int/HR-MDS/AML/advanced solid tumors	Phase 1	NCT03516591 NCT03144245 NCT04128423
	GTB-3550	Trispecific killer engager molecule (TriKE) against CD16/IL-15/CD33	HR-MDS/AML/ mast cell leukemia	Phase 1/2	NCT03214666
	IMGN779	CD33 antibody-drug conjugate	AML	Phase 1 completed	NCT02674763
	Lintuzumab	Anti-CD33 monoclonal antibody	AML	Phase 2 completed	NCT00528333
	225Ac-lintuzumab	Radioimmunoconjugate against CD33	AML	Phase 1/2 Phase 1/2	NCT02575963 NCT03867682
	Vadastuximab talirine	CD33 antibody-drug conjugate	AML	Phase 3 terminated	NCT02785900
TLR2	OPN-305	Anti-TLR2 monoclonal antibody	LR-MDS	Phase 2 completed	NCT02363491 NCT03337451
TLR4	Bortezomib	Proteasome inhibitor modulating TLR4 activity	LR/Int-MDS	Phase 2 completed	NCT01891968
NLRP3	MCC950	Blocks NACTH ATPase domain of NLRP3	MDS	In vitro/in-vivo	N/A
	MNS	Inhibits NLRP3 ATPase activity by cysteine modification	MDS	In vitro/in-vivo	N/A
	CY-09	Inhibits NLRP3 ATPase activity to block NLRP3 activation	MDS	In vitro/in-vivo	N/A
	OLT1177		Osteoarthritis, Schnitzler Syndrome	Phase 1/2	NCT01768975NCT03595371
ASC	Ibrutinib	BTK inhibitor that also binds to ASC and inhibits ASC aggregation	CLL HR-MDS AML	Phase 2 Phase 1 Phase 2 terminated	NCT03207555 NCT03359460 NCT02553941 NCT02351037
Caspase 1	VX-765	Peptidomimetic drug that blocks caspase 1 active site	Epilepsy/psoriasis	Phase 2 completed	NCT01048255 NCT00205465
	Parthenolide analog	Plant-based Michael acceptor inhibitor that directly inhibits caspase 1	Contact dermatitis detection	Phase 3 completed	NCT00640614
IL-1β	Canakinumab	IL-1β neutralizing monoclonal antibody	MDS/CML	Phase 1 Phase 2	NCT04810611 NCT04239157
	Rilonacept	Soluble decoy receptor that binds to IL-1β/IL-1α	Cryopyrin-associated periodic syndromes (CAPS)	N/A	N/A
	Anakinra	Antagonist of IL-1R	Cryopyrin-associated periodic syndromes (CAPS)	N/A	N/A
IRAK	CA - 4948	Small molecule inhibitor against IRAK4	MDS	Phase 1/2	NCT04278768
Wnt/β-catenin	CWP232291	Small molecule inhibitor of Wnt/β-catenin	MDS/AML	Phase 1 completed	NCT01398462